{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470618047
| IUPAC_name = (1''R'',5''S'')-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1''methyl''-indole-3-carboxylate
| image = Tropisetron.svg
| width = 250
| image2 = Tropisetron3Dan.gif
| width2 = 250

<!--Clinical data-->
| tradename = Navoban
| Drugs.com = {{drugs.com|international|tropisetron}}
| pregnancy_AU = B3
| legal_AU = S4
| legal_UK = POM
| routes_of_administration = Oral, [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability = ~60–80%
| protein_bound = 71%
| metabolism = [[Liver|Hepatic]] ([[CYP3A4]], [[CYP1A2]], [[CYP2D6]])
| elimination_half-life = 6–8 hours
| excretion = [[Kidney|Renal]], [[Feces|Fecal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 89565-68-4
| ATC_prefix = A04
| ATC_suffix = AA03
| PubChem = 72165
| IUPHAR_ligand = 260
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16736476
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6I819NIK1W
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02130
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 32269
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 496980
| synonyms =  ICS 205-930

<!--Chemical data-->
| C=17 | H=20 | N=2 | O=2 
| molecular_weight = 284.353 g/mol
| smiles = CN4[C@@H]1CC[C@H]4C[C@H](C1)OC(=O)c3cnc2ccccc23
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZNRGQMMCGHDTEI-ITGUQSILSA-N
}}

'''Tropisetron''' ([[International Nonproprietary Name|INN]]) is a [[serotonin]] [[5-HT3 antagonist|5-HT<sub>3</sub> receptor antagonist]] used mainly as an [[antiemetic]] to treat [[nausea]] and [[vomiting]] following [[chemotherapy]], although it has been used experimentally as an [[analgesic]] in cases of [[fibromyalgia]].<ref name="pain">{{cite journal | last1 = Müller | first1 = W. | first2 = T. | last2 = Stratz | title = Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron | journal = [[Scandinavian Journal of Rheumatology|Scand J Rheumatic Suppl.]] | volume = 119 | pages = 44–48 | date = 2004 | url = http://www.hubmed.org/fulltext.cgi?uids=15515413 | pmid = 15515413 | accessdate = 2007-05-17 | issue = 119}}</ref> The drug is available in a 5&nbsp;mg oral preparation or in 2&nbsp;mg intravenous form. It is marketed by [[Novartis]] in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as '''Navoban''', but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several Asian countries as '''Setrovel'''.

== Pharmacology ==
Tropisetron acts as both a selective [[5-HT3 antagonist|5-HT<sub>3</sub> receptor antagonist]] and [[Alpha-7 nicotinic receptor|α<sub>7</sub>-nicotinic receptor]] [[agonist]].<ref name="pmid11212100">{{cite journal | last1 = Macor | first1 = J.E. | last2 = Gurley | first2 = D. | last3 = Lanthorn | first3 = T. | last4 = Loch | first4 = J. | last5 = Mack | first5 = R.A. | last6 = Mullen | first6 = G. | last7 = Tran | first7 = O. | last8 = Wright | first8 = N. | last9 = Gordon | first9 = J.C.  |title=The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist |journal=[[Bioorganic & Medicinal Chemistry Letters]] |volume=11 |issue=3 |pages=319–21 |date=February 2001 |pmid=11212100 |doi= 10.1016/S0960-894X(00)00670-3|url=http://linkinghub.elsevier.com/retrieve/pii/S0960894X00006703}}</ref><ref name="pmid19374878">{{cite journal | last1 = Cui | first1 = R. | last2 = Suemaru | first2 = K. | last3 = Li | first3 = B. | last4 = Kohnomi | first4 = S. | last5 = Araki | first5 = H. |title=Tropisetron attenuates naloxone-induced place aversion in single-dose morphine-treated rats: role of alpha7 nicotinic receptors |journal=[[European Journal of Pharmacology]] |volume=609 |issue=1–3 |pages=74–7 |date=May 2009 |pmid=19374878 |doi=10.1016/j.ejphar.2008.12.051 |url= }}</ref>

== Adverse effects ==
Tropisetron is a well-tolerated drug with few side effects. [[Headache]], [[constipation]], and [[dizziness]] are the most commonly reported side effects associated with its use. [[Hypotension]], transient liver enzyme elevation, immune hypersensitivity syndromes and extrapyramidal side effects have also been associated with its use on at least one occasion.There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic [[cytochrome P450]] system and it has little effect on the metabolism of other drugs broken down by this system.

==Other uses==
As a biological stain and as [[trypanocide]].

== See also ==
* [[5-HT3_receptor_antagonist:drug_discovery_and_development|5-HT<sub>3</sub> receptor antagonist: Drug discovery and development]]
*[[Zatosetron]]
*[[Ricasetron]]
*[[Bemesetron]]
*[[Tropanserin]]
*[[Granisetron]]

== References ==
{{Reflist|2}}

== External links ==
* [http://www.tropisetron.com Official site]
* [http://www.medsafe.govt.nz/Profs/datasheet/n/navobancapinj.htm Navoban data sheet]


{{Antiemetics}}
{{Analgesics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Glycine receptor modulators}}
{{Nicotinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}

[[Category:Antiemetics]]
[[Category:5-HT3 antagonists]]
[[Category:Tropanes]]
[[Category:Indoles]]
[[Category:Carboxylate esters]]
[[Category:Glycine receptor agonists]]
[[Category:Glycine receptor antagonists]]
[[Category:Nicotinic agonists]]